Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label randomized study of PD-0332991 plus letrozole in advanced/metastatic breast cancer
2008-002392-27Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of palbociclib in breast cancer (2 arms), sponsored by Pfizer. Primary endpoint: Phase 1 safety and tolerability. Started Jan 2009; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-002392-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002392-27.